Tender detail
Supply of the 177Lu-PSMA radiopharmaceutical
Summary
Hradec Králové University Hospital is procuring recurring deliveries of the 177Lu-PSMA radiopharmaceutical, (177Lu) vipivotide tetraxetan, as an injection solution for intravenous use in the treatment of prostate cancer. The single lot covers deliveries to the hospital’s premises as needed over four years. The estimated contract value is CZK 59,345,304.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.